For Healthcare Professionals

A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma

clipboard-pencil

About the study

The purpose of this study is to assess the safety, tolerability and preliminary effectiveness of CC-92480 (BMS-986348) in novel therapeutic combinations for the treatment of Relapsed or Refractory Multiple Myeloma (RRMM).
user-3

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

Inclusion Criteria:

* Relapsed or refractory multiple myeloma (MM) and must:

  1. have documented disease progression during or after their last myeloma therapy
  2. be refractory to, intolerant to, or not a candidate for available, established therapies known to provide clinical benefit in MM
  3. Must have measurable disease
  4. Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1
  5. Agree to follow the CC-92480 Pregnancy Prevention Plan (PPP)

EXCLUSION CRITERIA

Exclusion Criteria:

  1. Known active or history of central nervous system (CNS) involvement of MM
  2. Plasma cell leukemia; Waldenstrom's macroglobulinemia; polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes (POEMS) syndrome; or clinically significant light-chain amyloidosis.
  3. Impaired cardiac function or clinically significant cardiac disease
  4. Previous SARS-CoV-2 infection within 14 days for asymptomatic or mild symptomatic infections or 28 days for severe/critical illness prior to Cycle 1 Day 1 (C1D1)
  5. For Part 1: received prior therapy with CC-92480
  6. For Part 2: received prior therapy with CC-92480, tazemetostat, BMS-986158, or trametinib
  7. Previously received allogeneic stem-cell transplant at any time or received autologous stem-cell transplant within 12 weeks of initiating study treatment
  8. Received any of the following within 14 days prior to initiating study treatment:
  1. Plasmapheresis
  2. Major surgery
  3. Radiation therapy other than local therapy for myeloma associated bone lesions
  4. Use of any systemic anti-myeloma drug therapy
  5. Used any investigational agents within 28 days or 5 half-lives (whichever is shorter) prior to initiating study treatment
  6. COVID-19 vaccine within 14 days prior to C1D1

Other protocol-defined inclusion/exclusion criteria apply

pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply


Contact the study center to learn if this study is a good match for you.
Phone iconCall 855-907-3286Email iconEmail Study Center

Study Details


Contition

Multiple Myeloma

Age

18+

Phase

PHASE1/PHASE2

Participants Needed

220

Est. Completion Date

Oct 12, 2026

Treatment Type

INTERVENTIONAL


Sponsor

Bristol-Myers Squibb

ClinicalTrials.gov NCT Identifier

NCT05372354

Study Number

CA057-003

Understanding Clinical Trials


Get answers to your questions about clinical trials.What is clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?
Vector

Interested?

Sign up to create a personal profile and 
receive news, resources, and alerts 
about clinical trials related to your conditions of interest.